GC
ADMA icon

Globeflex Capital’s ADMA Biologics ADMA Stock Holding History

Globeflex Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,924
Closed -$107K – 396
2026
Q1 		$107K Buy
11,924
+115
+1% +$1.81K 0.02% 359
2025
Q4 		$215K Buy
+11,809
New +$199K 0.03% 289
2025
Q2 		– Sell
-9,927
Closed -$197K – 421
2025
Q1 		$197K Hold
9,927
– – 0.02% 306
2024
Q4 		$170K Hold
9,927
– – 0.01% 329
2024
Q3 		$198K Sell
9,927
-457,845
-98% -$7.12M 0.02% 317
2024
Q2 		$5.23M Sell
467,772
-10,374
-2% -$87K 0.55% 47
2024
Q1 		$3.16M Buy
478,146
+212,400
+80% +$1.16M 0.31% 76
2023
Q4 		$1.2M Buy
265,746
+32,095
+14% +$119K 0.12% 160
2023
Q3 		$836K Sell
233,651
-2,672
-1% -$10.3K 0.1% 196
2023
Q2 		$872K Hold
236,323
– – 0.1% 191
2023
Q1 		$782K Buy
+236,323
New +$817K 0.1% 212

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Globeflex Capital's ADMA Position: Q2 2026 in Review

Globeflex Capital sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 11,924 shares — an estimated $107K sold.

Globeflex Capital first reported a position in ADMA in Q1 2023 and held it in 11 quarters. The position peaked at $5.23M in Q2 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Globeflex Capital reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Globeflex Capital sold 11,924 ADMA Biologics shares in Q2 2026, an estimated $107K.
  • Globeflex Capital first reported a position in ADMA Biologics in Q1 2023 and held it in 11 quarters.
  • Globeflex Capital's ADMA Biologics position peaked at $5.23M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.